International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationStandard (60 Gy) or Short-Course (40 Gy) Irradiation Plus Concomitant and Adjuvant Temozolomide for Elderly Patients With Glioblastoma: A Propensity-Matched Analysis
Introduction
Glioblastoma (GBM) is increasing among the elderly, and approximately one-third of all patients are aged >65 years (1). Radiation therapy (RT) is generally administered in this population, conferring a median survival from diagnosis of approximately 4 to 10 months 2, 3, 4, 5. Chemotherapy with the alkylating agent temozolomide (TMZ) or hypofractionated courses of RT are treatment options associated with similar survival benefits 6, 7, 8, 9, 10, 11, 12. In a randomized study of 100 patients aged ≥60 years with GBM who received either radical RT (60 Gy) or short-course RT (40 Gy), Roa et al (9) observed a median survival time of 5.1 months and 5.6 months for standard and short-term RT groups, respectively. A median survival time of 6 to 8 months has been reported with doses of 30-37.5 Gy in 6-15 daily fractions in some prospective studies 6, 7, 8.
Radical RT plus TMZ is standard treatment for adult patients with GBM and has been advocated as an effective approach in older patients with a good performance status. Although a few studies have shown promising survival times of 10 to 14 months with this regimen 13, 14, 15, 16, the likely toxicity is of concern, given the limited life expectancy of this patient population. Thus, many physicians may opt for less-aggressive treatment. Using a radiation schedule of 40 Gy in 15 fractions in combination with concomitant and adjuvant TMZ, we previously reported a median overall survival (OS) of 12.4 months and a median progression-free survival (PFS) of 6 months in 70 older patients aged ≥70 years with newly diagnosed GBM (17). This approach was associated with improved quality of life and performance status (18). Owing to results of the above prospective study, this particular regimen is often used at our institution as an alternative to standard radiochemotherapy for older patients with GBM.
To date there are no studies that have evaluated the clinical outcomes and toxicity of different RT schedules in combination with TMZ for older patients with GBM. With this in mind, we compared data from older patients aged ≥65 years with GBM who received standard or short-course RT in conjunction with TMZ. A propensity score analysis was done to adjust for between-group disparities of clinically relevant covariates.
Section snippets
Patients
Data collected from 329 patients aged ≥65 years with newly diagnosed, histologically confirmed GBM and Karnofsky performance status (KPS) ≥60 who received standard or short-course RT plus concomitant and adjuvant TMZ between June 2004 and October 2013 were evaluated in this tri-center, retrospective study. For patients treated at Sant'Andrea Hospital and Neuromed Institute all clinically relevant radiographic, surgical, and pathologic information was drawn from a prospectively maintained
Results
A total of 243 consecutive patients aged ≥65 years with newly diagnosed GBM received chemoradiotherapy between June 2004 and October 2013. Patient characteristics are shown in Table 1. Subjects received either standard (n=127) or short-course (n=116) RT. There were no statistically significant differences between groups in terms of gender, KPS scores, site of tumor, PTV, and MGMT promoter methylation status. However, patients given standard RT-TMZ were more likely to be younger and to undergo
Discussion
Clinical outcomes of this study, in which either standard or short-course RT was delivered with concomitant and adjuvant TMZ to patients aged ≥65 years with GBM, were similar in terms of 1-year survival, PFS, and OS. Hence, a chemoradiotherapeutic regimen of short-course versus standard RT plus TMZ does not seem to compromise patient survival in this context. The above findings are strengthened by propensity score analysis, which addresses potential bias when retrospective data of 2
References (26)
- et al.
Efficacy of radiotherapy for malignant gliomas in elderly patients
Int J Radiat Oncol Biol Phys
(1998) - et al.
Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution
Int J Radiat Oncol Biol Phys
(1998) - et al.
Radiotherapy is effective in patients with glioblastoma multiforme with a limited prognosis and in patients above 70 years of age: A retrospective single institution analysis
Radiother Oncol
(2005) - et al.
A prospective study of short course RT in poor prognosis glioblastoma multiforme
Int J Radiat Oncol Biol Phys
(1994) - et al.
Hypofractionated radiotherapy for poor prognosis malignant glioma: Matched pair survival analysis with MRC controls
Radiother Oncol
(2003) - et al.
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial
Lancet Oncol
(2012) - et al.
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial
Lancet Oncol
(2012) - et al.
Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma
Radiother Oncol
(2010) - et al.
Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma
Int J Radiat Oncol Biol Phys
(2012) - et al.
Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide
Int J Radiat Oncol Biol Phys
(2013)
Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients
Clin Neurol Neurosurg
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009
Neuro Oncol
Radiotherapy for glioblastoma in the elderly
N Engl J Med
Cited by (0)
This study was supported by a grant (C26A12TBP5) from University Sapienza, Rome, Italy (to R.M.E.).
Conflict of interest: none.